Brief: Axovant Gene Therapies Receives Orphan Drug Designation From FDA For AXO-AAV-GM1

Sio Gene Therapies

18/11/2019 12:41

Nov 18 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT GENE THERAPIES RECEIVES ORPHAN DRUG DESIGNATION
FROM FDA
FOR AXO-AAV-GM1 FOR THE TREATMENT OF GM1 GANGLIOSIDOSIS
    * AXOVANT GENE THERAPIES LTD -  EXPECTS TO ANNOUNCE 6-MONTH
DATA
FROM PART A OF AXO-AAV-GM1 REGISTRATIONAL PROGRAM IN MID-2020

Source text for Eikon:  ID:nGNXb3S26h 
Further company coverage:  AXGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))